Scientific Advisors

NK_Figuren5.jpg

Prof. Bob Pinedo MD, PhD, retired in 2008 as Professor of Medical Oncology at the VU University Medical Center. He was the founder and Chairman of the Board of the VUmc Cancer Center Amsterdam where research and patient care are closely interwoven.

He has received many international awards including the prestigious Dr Josef Steiner Cancer Research Foundation Award (1995), the NOW Spinoza Price (1997) and recently the David A. Karnofsky Memorial Award of the American Society of Clinical Oncology (2014). In 2008 Dr. Pinedo has been decorated by H.M. Queen Beatrix of the Netherlands as Knight in the Order of the Netherlands Lion. He is a member of the Royal Dutch Academy of Science and Arts and has published over 700 research articles in peer-reviewed international journals.

Cancer research and care for cancer patients is Dr. Pinedo's big passion. He is a strong believer in the use of NK cell immunotherapy for treatment of cancer patients. His scientific expertise and comprehensive network will help Glycostem to signal opportunities for its technology and products in the treatment of cancer.

Prof. Henk Verheul MD, PhD, is scientific co-director of the Cancer Center of Amsterdam and Professor of Medical Oncology. He is heading the Department of Medical Oncology in the VU University Medical Center, The Netherlands. 

Henk Verheul studied Medicine at the Medical School of the Erasmus University Rotterdam and did his PhD at the Department of Medical Oncology of the VUmc. During this time, he was a research fellow from 1996 - 1998 at the Department of Surgery and Vascular Biology at the Children’s Hospital at Harvard University (Boston, USA. After he obtained his PhD (Cum Laude) on the concomitant activation of angiogenesis and coagulation in cancer, Henk Verheul started clinical training to become a medical oncologist at the University Medical Center Utrecht. In 2005 he registered as a medical oncologist and started a translational research fellowship in drug development at the Sidney Kimmel Comprehensive Cancer Center at the John Hopkins Medical Institution (Baltimore, USA) at which he currently holds a visiting Professorship position. In addition, he is an instructor for Palliative Care Management in Oncology and since 2016 chair of the Internal Medicine Division at VUmc.

Prof. Ulrike Köhl MD, PhD, is managing director at the Fraunhofer Institute for Cell Therapy and Immunology (IZI). As the newly appointed professor of immuno-oncology at Leipzig University, Prof. Köhl has also managed the Institute of Clinical Immunology at Leipzig University Hospital since December 2017. Previously, as a scientist specialising in cellular immunotherapies, she worked as a professor at the Hannover Medical School.

Prof. Köhl has extensively researched in the field of cell and gene therapy – most recently at Hannover Medical School where she managed the Institute of Cell Therapeutics from 2012 onwards. Previously, the biologist and medical expert worked in various functions at Frankfurt am Main University Hospital for many years. Moreover, her focus in experimental medicine and, in particular, the development of immune therapies also took her to the MD Anderson Cancer Center in Houston, USA. 

Wim Jongen PhD, has more than 25 years of experience in R&D and Business Development in life sciences. Wim has been active in the last 7 years as investment manager in Life Sciences, is currently active as chairman of the non-executive board of directors of NTRC B.V. and has acted as chairman of the board of directors of a number of Life Science companies.

Prof. Hareth Nahi MD, PhD, is a specialist in internal medicine and hematology, and has held the position of senior consultant in the Department of Hematology at the Karolinska University Hospital, Stockholm, Sweden since 2003. He is also Associate Professor in Hematology and Group Leader at the Center for Hematology and Regenerative Medicine (HERM) at the Dept of Medicine Huddinge, Karolinska Institutet since 2009, the research program focuses on cytogenetic and therapeutic mechanisms in multiple myeloma.

Dr Nahi has been Chair of the Nordic Myeloma Study Group (NMSG) from November 2015 to present.  His other academic distinctions and merits include being a Member of the scientific committee at Black Swan Research initiative (BSRI).

Past appointments include Guest Editor for Lancet Oncology, Consultant for Cell Protect (cancer immunotherapy company) and Co-founder of Vycellix and Cell Protect. Dr Nahi is an author and co-author of more than 80 peer-reviewed publications and has participated in many clinical trials focusing on multiple myeloma but also involving patients with AML and lymphomas.

Prof. Akihiro "Sam" Shimosaka PhD, serves as the Chief Executive Officer and President of BioOne Corporation and Beijing BioOne Medical Technology Co., Ltd. Prior to this he also served as Vice President of Licensing Department, Pharmaceutical Division of Kirin Brewery Company and as Advisor to Medinet Co. Ltd. Additionally, dr. Shimosaka has extensive domestic and international experience in early and later stage biotechnology companies in research and development, product development and regulatory issues. Dr. Shimosaka also held the following positions: Member of the Scientific & Clinical Advisory Board of Vaccinex, Inc. and Member of Scientific Advisory Board at IR Biosciences Holdings Inc. Dr. Shimosaka is a Honorary Professor at Institute of Hematology, Peking Union Medical College, Chinese Academy of Medical Sciences, Peking University School of Oncology and visiting professor at Tokyo Institute of Technology.

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.